Novartis

News

Novartis updates on Sandoz finances ahead of spin-off

Novartis confirmed this morning that it expects to complete the separation of its generic and biosimilar medicines unit Sandoz into an independent company on or around 4th

News

Novartis hits back at Entresto selection on Medicare list

Novartis has responded to the inclusion of its heart failure blockbuster Entresto on the list of the first 10 drugs that will be subject to Medicare pricing negotiations,

News

Novartis gets a win in chronic hives, setting up filings

Novartis' big-selling IgE inhibitor Xolair has been a mainstay of treatment for refractory chronic spontaneous urticaria (CSU) for many years, but its efforts to find a su

News

Dosing prompts Novartis to tap Ionis for second Lp(a) drug

Novartis has turned to Ionis for another cardiovascular disease drug, putting $60 million down for a follow-up to lipoprotein(a)-targeting drug pelacarsen, which is now in

News

FDA okays Daiichi Sankyo’s Vanflyta for first-line AML

Daiichi Sankyo’s Vanflyta has become the first drug in the US to be approved for newly-diagnosed acute myeloid leukaemia (AML) with FLT3-ITD mutations, nearly four years a

News

TIGIT underwhelms again as Novartis ducks out

The role of TIGIT as a target for immuno-oncology therapies has been called into question again after it was revealed that Novartis handed back rights to a drug partnered

Novartis updates on Sandoz finances ahead of spin-off

Novartis hits back at Entresto selection on Medicare list

Novartis gets a win in chronic hives, setting up filings

Dosing prompts Novartis to tap Ionis for second Lp(a) drug

FDA okays Daiichi Sankyo’s Vanflyta for first-line AML

TIGIT underwhelms again as Novartis ducks out

CDC panel votes to scrap hepatitis B birth dose advice

How to meet your physicians where they are online

Novartis

Editor's Picks